Stimulator of interferon genes protein · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Stimulator of interferon genes protein shows clinical signal disease relevance led by head and neck malignant neoplasia. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q86WV6. Start with head and neck malignant neoplasia, then reuse UniProt Q86WV6 as the stable protein anchor across project notes and exports.
Start with head and neck malignant neoplasia, then reuse UniProt Q86WV6 as the stable protein anchor across project notes and exports.
Stimulator of interferon genes protein shows clinical signal disease relevance led by head and neck malignant neoplasia. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with head and neck malignant neoplasia because it currently carries clinical signal support. Linked drugs include ADU-S100. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyStimulator of interferon genes protein
Review this target as Stimulator of interferon genes protein, mapped to UniProt Q86WV6. Sequence length is 379 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Stimulator of interferon genes protein as ChEMBL target CHEMBL4523377, mapped to UniProt Q86WV6. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Stimulator of interferon genes protein is the right protein anchor across sources, using UniProt Q86WV6 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why head and neck malignant neoplasia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Stimulator of interferon genes protein |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q86WV6 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Stimulator of interferon genes protein |
| UniProt Accession | Q86WV6 |
| Component Type | Protein |
| Sequence Length | 379 aa |
Stimulator of interferon genes protein
Review this target as Stimulator of interferon genes protein, mapped to UniProt Q86WV6. Sequence length is 379 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Stimulator of interferon genes protein shows clinical signal disease relevance led by head and neck malignant neoplasia. 1 more disease program remain visible in the same review block.
Start review with head and neck malignant neoplasia because it currently carries clinical signal support. Linked drugs include ADU-S100. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5188233 | 10.22 | Kd | 0.06 | Preclinical |
| CHEMBL5201766 | 10.21 | IC50 | 0.0623 | Preclinical |
| CHEMBL4465054 | 9.96 | Kd | 0.11 | Preclinical |
| CHEMBL6003926 | 9.72 | Ki | 0.19 | Preclinical |
| CHEMBL5967512 | 9.71 | Kd | 0.195 | Preclinical |
| CHEMBL5844854 | 9.7 | Ki | 0.2 | Preclinical |
| CHEMBL5197229 | 9.7 | Kd | 0.2 | Preclinical |
| CHEMBL5911979 | 9.7 | Ki | 0.2 | Preclinical |
| CHEMBL6003926 | 9.7 | Kd | 0.2 | Preclinical |
| CHEMBL5175703 | 9.7 | IC50 | 0.2 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 520 | 473 | 6.1 |
| single protein format | 79 | 288 | 6.4 |
| assay format | 54 | 388 | 6.2 |
| tissue-based format | 5 | 13 | 5.4 |
| cell membrane format | 1 | 8 | 6.5 |
| microsome format | 1 | 1 | 8.7 |